The initiation of the pivotal SUNRISE-FA 2 trial and RMAT designation for LX2020 are significant de-risking catalysts. Monitor for the 12-month LX2020 data update in Q4 2026 and continued enrollment updates for SUNRISE-FA 2. The strong cash position reduces near-term dilution risk.
Price Chart
Executive Summary
Lexeo Therapeutics reported Q2 2026 financial results with a net loss of $0.30 per share, slightly better than the $0.30 consensus. The key catalysts are the initiation of the SUNRISE-FA 2 pivotal trial for LX2006 in Friedreich ataxia cardiomyopathy (topline data expected 2H 2027) and the FDA granting RMAT designation for LX2020 in PKP2-ACM. The company has $234.2M in cash, sufficient into 2028, funding through the pivotal readout and potential BLA submission.
Key Financial Metrics
Key Facts
- Initiated SUNRISE-FA 2 pivotal trial for LX2006 with first patient enrolled in June 2026; topline data expected 2H 2027.
- FDA granted RMAT designation for LX2020 in PKP2-ACM, supporting expedited development.
- Cash, cash equivalents, and investments of $234.2 million as of June 30, 2026, providing runway into 2028.
- Net loss of $25.9 million ($0.30 per share) for Q2 2026, compared to $26.1 million ($0.60 per share) in Q2 2025.
- 12-month data update for all high-dose LX2020 participants expected in Q4 2026.
Financial Impact
Net loss of $25.9M in Q2 2026 vs $26.1M in Q2 2025; cash burn rate manageable with $234.2M cash runway into 2028.
Risk Factors
- Topline data from SUNRISE-FA 2 not expected until 2H 2027, leaving a long period with no binary catalyst.
- Phase I/II LX2006 data is based on small sample sizes (n=6 for LVMi); pivotal trial results may not replicate.
- LX2020 is still early-stage (Phase I/II, n=10); RMAT designation does not guarantee approval.
- Pre-revenue biotech with no approved products; relies entirely on pipeline success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-345722 |
| Document: lxeo-20260812.htm | 0001193125-26-345722 |
| Document: lxeo-ex99_2.htm | 0001193125-26-345722 |
| Document: 0001193125-26-345722-index-headers.html | 0001193125-26-345722 |
| Document: 0001193125-26-345722-index.html | 0001193125-26-345722 |
| Document: 0001193125-26-345722.txt | 0001193125-26-345722 |
| 8-K Data (Synthetic) | 0001193125-26-345722 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | SC 13G | $2.74 $3.02 | ▲ +10.22% | ▲ +11.37% | $2.75 (+0.36%) |
Sep 22, 2026 5w ago | 8-K | $4.07 $3.42 | ▼ −15.97% | ▼ −14.78% | $2.75 (−32.43%) |
Aug 12, 2026 10w ago | 8-K | $4.87 $5.37 | ▲ +10.27% | ▲ +10.71% | $2.75 (−43.53%) |
Aug 12, 2026 10w ago | Press Release | $4.87 $5.37 | ▲ +10.27% | ▲ +10.71% | $2.75 (−43.53%) |
Jul 1, 2026 16w ago | Insider Cluster | $4.69 $5.05 | ▲ +7.68% | ▲ +6.75% | $2.75 (−41.36%) |
Jun 17, 2026 18w ago | Press Release | $4.93 $4.70 | ▼ −4.67% | ▼ −3.00% | $2.75 (−44.22%) |
Jun 15, 2026 19w ago | 8-K | $4.65 $5.04 | ▲ +8.39% | ▲ +9.77% | $2.75 (−40.86%) |
Jun 12, 2026 19w ago | Institutional Cluster | $4.37 $4.93 | ▲ +12.81% | ▲ +12.14% | $2.75 (−37.07%) |
May 20, 2026 22w ago | Insider Cluster | $5.23 $5.14 | ▼ −1.72% | ▼ −3.57% | $2.75 (−47.42%) |
May 11, 2026 24w ago | 8-K | $6.12 $4.71 | ▼ −23.04% | ▼ −22.95% | $2.75 (−55.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers